IL192485A0 - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - Google Patents

Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Info

Publication number
IL192485A0
IL192485A0 IL192485A IL19248508A IL192485A0 IL 192485 A0 IL192485 A0 IL 192485A0 IL 192485 A IL192485 A IL 192485A IL 19248508 A IL19248508 A IL 19248508A IL 192485 A0 IL192485 A0 IL 192485A0
Authority
IL
Israel
Prior art keywords
derivatives
uptake inhibitors
monoamine neurotransmitter
novel chromen
chromen
Prior art date
Application number
IL192485A
Other languages
English (en)
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of IL192485A0 publication Critical patent/IL192485A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
IL192485A 2006-02-17 2008-06-26 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors IL192485A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600233 2006-02-17
PCT/EP2007/051401 WO2007093604A1 (en) 2006-02-17 2007-02-13 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Publications (1)

Publication Number Publication Date
IL192485A0 true IL192485A0 (en) 2009-02-11

Family

ID=39272807

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192485A IL192485A0 (en) 2006-02-17 2008-06-26 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Country Status (15)

Country Link
US (1) US8153797B2 (https=)
EP (2) EP1989202B1 (https=)
JP (1) JP2009526816A (https=)
KR (1) KR20080096833A (https=)
CN (1) CN101405287B (https=)
AR (1) AR059546A1 (https=)
AU (1) AU2007216535A1 (https=)
BR (1) BRPI0707853A2 (https=)
CA (1) CA2641916A1 (https=)
IL (1) IL192485A0 (https=)
NO (1) NO20083955L (https=)
RU (1) RU2008129865A (https=)
TW (1) TW200800980A (https=)
WO (1) WO2007093604A1 (https=)
ZA (1) ZA200805908B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070061846A (ko) * 2004-09-30 2007-06-14 뉴로서치 에이/에스 신규한 크로멘-2-온 유도체 및 모노아민 신경전달물질재흡수 억제제로서의 이의 용도
CA2673315A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2007336291A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8697721B2 (en) * 2009-05-15 2014-04-15 Aniona Aps Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011092061A1 (en) 2010-01-29 2011-08-04 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011117289A1 (en) 2010-03-25 2011-09-29 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
WO2012000881A1 (en) 2010-07-02 2012-01-05 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
EE03566B1 (et) 1995-11-02 2001-12-17 Neurosearch A/S Kondenseerunud tropaanderivaadid, nende valmistamine ja kasutamine
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
US5916914A (en) * 1997-08-08 1999-06-29 Warner-Lambert Company Compounds and method of treating psychosis and schizophrenia
EP1397358A1 (en) * 2001-05-23 2004-03-17 Neurosearch A/S Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2488635C (en) 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US7538233B2 (en) 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
AU2005288914B2 (en) * 2004-09-30 2011-05-19 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1828173A1 (en) 2004-12-17 2007-09-05 Neurosearch A/S Enentiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
CA2673315A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2007336291A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
EP2311835A1 (en) 2011-04-20
NO20083955L (no) 2008-09-16
TW200800980A (en) 2008-01-01
CN101405287B (zh) 2011-05-18
ZA200805908B (en) 2009-10-28
RU2008129865A (ru) 2010-03-27
EP1989202B1 (en) 2012-07-25
KR20080096833A (ko) 2008-11-03
BRPI0707853A2 (pt) 2011-05-10
CN101405287A (zh) 2009-04-08
US8153797B2 (en) 2012-04-10
CA2641916A1 (en) 2007-08-23
WO2007093604A1 (en) 2007-08-23
US20100227883A1 (en) 2010-09-09
AU2007216535A1 (en) 2007-08-23
JP2009526816A (ja) 2009-07-23
EP1989202A1 (en) 2008-11-12
AR059546A1 (es) 2008-04-09

Similar Documents

Publication Publication Date Title
HRP20181622T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
IL192613A0 (en) Cycloalkylamines as monoamine reuptake inhibitors
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
PL2040728T3 (pl) FKBP-L i jego zastosowanie jako inhibitora angiogenezy
PT2094263E (pt) Derivados da 2-adamantil-butiramida como inibidores seletivos da 11-beta-hsd1
ZA200807447B (en) Thieno-Pyridine derivatives as MEK inhibitors
IL210843A0 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
IL197528A0 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
GB0601143D0 (en) Uses, methods and compositions
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL209406A0 (en) Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL192485A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL195014A0 (en) Benzazepine derivatives as monoamine reuptake inhibitors
IL187575A0 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
EP2029132A4 (en) ANTIHISTAMINE COMPOSITIONS AND THEIR USE
IL198762A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
GB0622399D0 (en) Novel compositions and uses thereof
GB0617171D0 (en) Novel compositions and methods
ZA200903278B (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL180777A0 (en) Novel chromen-2- one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL178734A0 (en) Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL206303A0 (en) Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors